A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- UZ Leuven, Leuven
- CHU UCL St-Luc, Bruxelles
- UZ Antwerpen, Antwerpen
- AZ Maria Middelares, Gent
- AZ Delta, Roeselare
